BACKGROUND AND AIMS: The increase in breast cancer incidence over recent decades has been accompanied by an increase in the frequency of metabolic syndrome. Several studies suggest that breast cancer risk is associated with the components of metabolic syndrome (high serum glucose and triglycerides, low HDL-cholesterol, high blood pressure, and abdominal obesity), but no prospective study has investigated risk in relation to the presence of explicitly defined metabolic syndrome. We investigated associations between metabolic syndrome, its components, and breast cancer risk in a nested case-control study on postmenopausal women of the ORDET cohort. METHODS AND RESULTS: After a median follow-up of 13.5 years, 163 women developed breast cancer; metabolic syndrome was present in 29.8%. Four matched controls per case were selected by incidence density sampling, and rate ratios were estimated by conditional logistic regression. Metabolic syndrome (i.e. presence of three or more metabolic syndrome components) was significantly associated with breast cancer risk (rate ratio 1.58 [95% confidence interval 1.07-2.33]), with a significant risk increase for increasing number of components (P for trend 0.004). Among individual metabolic syndrome components, only low serum HDL-cholesterol and high triglycerides were significantly associated with increased risk. CONCLUSIONS: This prospective study indicates that metabolic syndrome is an important risk factor for breast cancer in postmenopausal women. Although serum HDL-cholesterol and triglycerides had the strongest association with breast cancer, all components may contribute to increased risk by multiple interacting mechanisms. Prevention or reversal of metabolic syndrome by life-style changes may be effective in preventing breast cancer in postmenopausal women. Copyright 2009 Elsevier B.V. All rights reserved.
BACKGROUND AND AIMS: The increase in breast cancer incidence over recent decades has been accompanied by an increase in the frequency of metabolic syndrome. Several studies suggest that breast cancer risk is associated with the components of metabolic syndrome (high serum glucose and triglycerides, low HDL-cholesterol, high blood pressure, and abdominal obesity), but no prospective study has investigated risk in relation to the presence of explicitly defined metabolic syndrome. We investigated associations between metabolic syndrome, its components, and breast cancer risk in a nested case-control study on postmenopausal women of the ORDET cohort. METHODS AND RESULTS: After a median follow-up of 13.5 years, 163 women developed breast cancer; metabolic syndrome was present in 29.8%. Four matched controls per case were selected by incidence density sampling, and rate ratios were estimated by conditional logistic regression. Metabolic syndrome (i.e. presence of three or more metabolic syndrome components) was significantly associated with breast cancer risk (rate ratio 1.58 [95% confidence interval 1.07-2.33]), with a significant risk increase for increasing number of components (P for trend 0.004). Among individual metabolic syndrome components, only low serum HDL-cholesterol and high triglycerides were significantly associated with increased risk. CONCLUSIONS: This prospective study indicates that metabolic syndrome is an important risk factor for breast cancer in postmenopausal women. Although serum HDL-cholesterol and triglycerides had the strongest association with breast cancer, all components may contribute to increased risk by multiple interacting mechanisms. Prevention or reversal of metabolic syndrome by life-style changes may be effective in preventing breast cancer in postmenopausal women. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: R Kaaks; S Rinaldi; T J Key; F Berrino; P H M Peeters; C Biessy; L Dossus; A Lukanova; S Bingham; K-T Khaw; N E Allen; H B Bueno-de-Mesquita; C H van Gils; D Grobbee; H Boeing; P H Lahmann; G Nagel; J Chang-Claude; F Clavel-Chapelon; A Fournier; A Thiébaut; C A González; J R Quirós; M-J Tormo; E Ardanaz; P Amiano; V Krogh; D Palli; S Panico; R Tumino; P Vineis; A Trichopoulou; V Kalapothaki; D Trichopoulos; P Ferrari; T Norat; R Saracci; E Riboli Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: S E Hankinson; W C Willett; G A Colditz; D J Hunter; D S Michaud; B Deroo; B Rosner; F E Speizer; M Pollak Journal: Lancet Date: 1998-05-09 Impact factor: 79.321
Authors: Rudolf Kaaks; Franco Berrino; Timothy Key; Sabina Rinaldi; Laure Dossus; Carine Biessy; Giorgio Secreto; Pilar Amiano; Sheila Bingham; Heiner Boeing; H Bas Bueno de Mesquita; Jenny Chang-Claude; Françoise Clavel-Chapelon; Agnès Fournier; Carla H van Gils; Carlos A Gonzalez; Aurelio Barricarte Gurrea; Elena Critselis; Kay Tee Khaw; Vittorio Krogh; Petra H Lahmann; Gabriele Nagel; Anja Olsen; N Charlotte Onland-Moret; Kim Overvad; Domenico Palli; Salvatore Panico; Petra Peeters; J Ramón Quirós; Andrew Roddam; Anne Thiebaut; Anne Tjønneland; Ma Dolores Chirlaque; Antonia Trichopoulou; Dimitrios Trichopoulos; Rosario Tumino; Paolo Vineis; Teresa Norat; Pietro Ferrari; Nadia Slimani; Elio Riboli Journal: J Natl Cancer Inst Date: 2005-05-18 Impact factor: 13.506
Authors: Katherine W Reeves; Vicki McLaughlin; Lisa Fredman; Kristine Ensrud; Jane A Cauley Journal: Cancer Causes Control Date: 2012-06-02 Impact factor: 2.506
Authors: Lisa J Martin; Olga Melnichouk; Ella Huszti; Philip W Connelly; Carolyn V Greenberg; Salomon Minkin; Norman F Boyd Journal: J Natl Cancer Inst Date: 2015-03-28 Impact factor: 13.506
Authors: Christopher J Moulton; Rudy J Valentine; Donald K Layman; Suzanne Devkota; Keith W Singletary; Matthew A Wallig; Sharon M Donovan Journal: Nutr Metab (Lond) Date: 2010-01-10 Impact factor: 4.169
Authors: Amy L Strong; Julie A Semon; Thomas A Strong; Tatyana T Santoke; Shijia Zhang; Harris E McFerrin; Jeffrey M Gimble; Bruce A Bunnell Journal: Stem Cells Date: 2012-12 Impact factor: 6.277